Back to search

Democritus University of Thrace (DUTH)

Διερεύνηση της προγνωστικής και προβλεπτικής σημασίας επιγενετικών βιοδεικτών στον καρκίνο του μαστού και άλλους γυναικολογικούς καρκίνους

Abstract

dc:description

DNA methylation is the most widely studied epigenetic mechanism. In cancer, aberrant methylation is usually observed in tumor suppressor and metastasis suppressor gene promoters, resulting in loss of their protective role. It has been demonstrated that the abnormal methylation patterns of DNA found in tumors can also be detected in biomaterials of «liquid biopsy» of patients and can be therefore evaluated as minimally invasive biomarkers of clinical value. Circulating Cell-Free DNA (ccfDNA) can be easily isolated from biological fluids such as plasma/serum. Thus, numerous studies are being contacted in order to identify and validate DNA methylation signatures on ccfDNA. In order to detect and evaluate such biomarkers, we studied gene specific DNA methylation patterns in cervical and breast cancer. Our study was implemented in three distinct parts. In uterine cervix, it has been proved that High Risk Human Papillovirus (HRHPV) infection can cause aberrant DNA methylation. We assessed for the first time DNA methylation of the cancer-related genes BRMS1 and WNT5A in cervical smears of 64 women with no infection by HRHPV, 70 women with proven HRHPV infection and in cervical tissue biopsies using quantitative Methylation specific PCR (qMSP). Methylation of BRMS1 promoter was detected statistically significant more often in women with no HRHPV infection in relation to women with HRHPV infection or pathological histology. On the contrary, methylation of WNT5A promoter was detected statistically significant more frequently in women with HRHPV infection and pathological histology. Furthermore, we studied the protein expression of BRMS1 using immunohistochemistry in biopsies of cervical tissue which revealed nuclear BRMS1 protein staining in normal HRHPV–free cervix, in intraepithelial neoplasia and in malignant tissue, where staining was occasionally also cytoplasmic. In cancer, expression was stronger in the more differentiated cancer blasts and was lost in low differentiated cancer blasts, probably due to DNA methylation. In the second part, we analyzed the kinetics and release mechanism of ccfDNA in vitro. The study was conducted in cultures of HeLa and MCF-7 cells. Normalized indexes of ccfDNA per cell population decreased over time of culture but were significantly elevated after exposure to the IC50 doses of 5‐azacytidine (5‐AZA‐CR). Fragment‐size profiling was indicative of active release, whereas exposure to 5‐AZA‐CR induced the release of additional shorter fragments, indicative of apoptosis. Also, using qMSP, we observed that the DNA methylation profile of SOX17, WNT5A, MSH2, KLK10 and GATA3 in cells gDNA was identical to the corresponding ccfDNA and followed accurately changes caused by 5‐AZA‐CR.In breast cancer, we evaluated the prognostic and predictive potential of ccfDNA related parameters. Groups consisted of 150 and 16 breast cancer patients under adjuvant and neoadjuvant therapy respectively, 34 patients with metastatic disease and 35 healthy volunteers. Direct quantification of ccfDNA in plasma revealed elevated concentrations correlated to the incidence of death, shorter PFS and non-response to pharmacotherapy in patients with metastatic breast cancer. Also, greater number of ccfDNA fragments was associated with elevated levels of ccfDNA, tumor size and incidence of death. The methylation status of studied genes KLK10, SOX17, WNT5A, MSH2 except for GATA3 was more frequently methylated in all patient groups than in healthy individuals. Furthermore, statistically significant differences were observed between the methylation status of WNT5A, KLK10 and SOX17 genes with the clinicopathological characteristics and the course of the disease. Classification analysis by a fully automated, machine learning software produced a single-parametric linear model using ccfDNA plasma concentration values, with great discriminating power to predict response to pharmacotherapy (AUC 0.803, 95% CI [0.606, 1.000]) in the metastatic group. Two more multi-parametric signatures were produced for the metastatic group, predicting survival and disease outcome. Finally, a multiple logistic regression model was constructed, discriminating between patient groups and healthy individuals. Upon prospective clinical evaluation, all the classifiers produced could aid accurate prognosis and prediction in metastatic breast cancer.Overall, our study greatly enriches knowledge about ccfDNA biology in cancer and reveals its significance as a liquid biopsy biomaterial. We believe that specific methylation patterns as detected in either cervical smears or ccfDNA may be minimally invasive epigenetic /pharmacoepigenetic biomarkers that will assist the clinical management of the studied neoplasms.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Panagopoulou-Pantazi, Maria
  • Παναγοπούλου-Πανταζή, Μαρία

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45446

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Panagopoulou-Pantazi, Maria; Παναγοπούλου-Πανταζή, Μαρία. Διερεύνηση της προγνωστικής και προβλεπτικής σημασίας επιγενετικών βιοδεικτών στον καρκίνο του μαστού και άλλους γυναικολογικούς καρκίνους. Democritus University of Thrace (DUTH), 2019. http://hdl.handle.net/10442/hedi/45446